SCHEMBL3394657

SCHEMBL3394657

Cc1nc2cc(C(=O)N[C@@H]3CCCc4ccccc43)ccc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 4/20 0.62
TAS1R1 Q7RTX1 4/20 0.62
LMNA P02545 3/20 0.62
HTT P42858 2/20 0.58
KMT2A Q03164 5/20 0.56
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 3/20 0.56
TAS1R2 Q8TE23 2/20 0.56
MEN1 O00255 4/20 0.56
HPGD P15428 2/20 0.55
CYP2D6 P10635 2/20 0.55
THRB P10828 1/20 0.55
MMP14 P50281 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CYP1A2 P05177 1/20 0.55
PKM P14618 1/20 0.55
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394421 1.00 TAS1R3 (0.62) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL31759158 0.85 ALDH1A1 (0.57) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL31759288 0.85 ALDH1A1 (0.57) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL31759141 0.81 ALDH1A1 (0.62) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL31759243 0.81 ALDH1A1 (0.62) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL3394738 0.81 CYP2D6 (0.60) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL3392193 0.81 HTT (0.60) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL6511815 0.81 HTT (0.60) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL6514681 0.81 CYP2D6 (0.60) TAS1R3TAS1R1LMNAHTTKMT2A
SCHEMBL14863654 0.79 HTT (0.60) TAS1R3TAS1R1LMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370530-B1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL SANOFI AVENTIS DEUTSCHLAND (DE) 2010-12-29 EP disclosed
US-6949556-B2 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-27 US disclosed
EP-1370530-A1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL Aventis Pharma Deutschland GmbH (DE) 2003-12-17 EP disclosed
US-20030022935-A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-01-30 US disclosed
WO-2002064565-A1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022935-A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents VEGFA, EDNRA, NR1H2 TAS1R3 2306/4885TAS1R1 1843/4885LMNA 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.